We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Newsroom
Keep posted about
our latest developments
and achievements
02.04.2024: World Autism Awareness Day
Link to photo source (UN) At Ksilink, it is one of our core missions to develop new therapeutic modalities to treat autism and particularly a rare form called Phelan McDermid...
New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease
New Study on the Impact of Endocrine Disrupting Chemicals on Parkinson’s Disease Ksilink, in collaboration with researchers from the University of Chieti in Italy, has published...
Review Article in JAMA Psychiatry
Schumann G, Andreassen OA, Banaschewski T, et al. Addressing Global Environmental Challenges to Mental Health Using Population Neuroscience: A Review. JAMA Psychiatry....
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany